Replies to post #14787 on ANI Pharmaceuticals (ANIP)

[Easka]

Overall I think Nikhil was little nervous, maybe because he had a little audience.
From 10K Samy is authorized to sell up to 400000 more shares between 3/4/24 and 11/29/24. He sold more a couple of days ago.

[Just the facts maam]

Easka, Nikhil is very conservative in estimating the potential market. He stated that he overall Acth sales in 2022 and 2023 were approx. $560 million. Which makes recapturing the prescription totals of 2017 a $1.12 billion market.

He is not talking about the potential peak market. I believe recapturing the prescription totals to 2017 levels still only covered between 30,000 and 35,000 prescription. This is less than 1% of the potential 4 million potential patients who are refractory to standard treatments which were identified when ANIP acquired Corti from Merck. I believe the holistic approach ANIP is is using in selling Corti will expand the market way beyond the 2017 numbers, especially when armed with the 1ml vial.

JMHO